{"nctId":"NCT04298229","briefTitle":"Efficacy and Safety of Dapagliflozin in Acute Heart Failure","startDateStruct":{"date":"2020-04-01","type":"ACTUAL"},"conditions":["Heart Failure","Diabetes Mellitus, Type 2"],"count":240,"armGroups":[{"label":"Protocolized diuretic therapy","type":"ACTIVE_COMPARATOR","interventionNames":["Other: Protocolized Diuretic Therapy"]},{"label":"Protocolized diuretic therapy plus SGLT2 inhibitor therapy","type":"EXPERIMENTAL","interventionNames":["Drug: Dapagliflozin 10 MG","Other: Protocolized Diuretic Therapy"]}],"interventions":[{"name":"Dapagliflozin 10 MG","otherNames":["sodium-glucose cotransporter-2(SGLT2) inhibitors"]},{"name":"Protocolized Diuretic Therapy","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Age of 18 years or older\n* Randomized within 24 of presentation during a hospital admission for hypervolemic decompensated heart failure defined as:\n\n  * pulmonary artery catheterization with a pulmonary capillary wedge pressure greater than 19mmHg plus a systemic physical exam finding of hypervolemia (peripheral edema, ascites, or pulmonary edema on auscultation)\n  * in the absence of pulmonary artery catheterization data 2 of the following signs or symptoms: peripheral edema, ascites, jugular venous pressure \\> 10mmHg, orthopnea, paroxysmal nocturnal dyspnea, 5-pound weight gain, or signs of congestion on chest x-ray or lung ultrasound\n* Planned use of IV loop diuretic therapy during current hospitalization\n* eGFR of 25 ml/min/1.73m2 by the MDRD equation or greater\n\nExclusion Criteria:\n\n* Type 1 diabetes\n* Serum glucose \\< 80mg/dl at enrollment\n* Systolic blood pressure \\< 90mmHg at enrollment\n* Requirement of intravenous inotropic therapy or anticipated need during the study\n* History of hypersensitivity to any SGLT2 inhibitors\n* Women who are pregnant or breastfeeding\n* Severe anemia (Hemoglobin \\< 7.5g/dl)\n* Severe uncorrected aortic or mitral stenosis\n* Inability to perform standing weights or measure urine output accurately\n* History of diabetic ketoacidosis\n* Scheduled combination nephron blockade with loop and thiazide therapy as an outpatient for more than 7 days prior to admission (excluding HCTZ \\< 50mg for blood pressure)\n* Diffuse anasarca with 4+ edema and projected hypervolemia exceeding 40-pounds\n* Severe hepatic impairment (Child-Pugh class C)\n* Clinical picture consistent with acute myocardial infarction including troponin rise and fall or ischemic changes on electrocardiogram\n* Site investigator determines the subject is not a good candidate to participate in the study at this tine","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Cumulative Change in Weight (Kilograms) Per 40mg of IV Furosemide Equivalents, Adjusted for Baseline Weight","description":"cumulative change in weight (kilograms) per 40mg of IV furosemide equivalents from enrollment to day 5 or discharge (if earlier) between protocolized diuretic therapy and dapagliflozin plus protocolized diuretic therapy guided by urine output","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.31","spread":null},{"groupId":"OG001","value":"-0.42","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Inpatient Worsening Heart Failure","description":"Number of participants with worsening heart failure during hospitalization requiring IV inotropic therapy with dobutamine, milrinone, or dopamine or admission to an intensive care unit as adjudicated by the Clinical Event Adjudication Committee","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Hospital Readmission","description":"Hospital readmission within 30 days of discharge for heart failure or diabetic reasons as adjudicated by the Clinical Event Adjudication Committee","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"19","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":7,"n":119},"commonTop":["Hypoglycemia","HF exacerbation"]}}}